Cost-Effectiveness Evaluation of a Collaborative Patient Education Hypertension Intervention in Utah
Article first published online: 3 OCT 2012
© 2012 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 14, Issue 11, pages 760–766, November 2012
How to Cite
Trogdon, J. G., Larsen, B., Larsen, D., Salas, W. and Snell, M. (2012), Cost-Effectiveness Evaluation of a Collaborative Patient Education Hypertension Intervention in Utah. The Journal of Clinical Hypertension, 14: 760–766. doi: 10.1111/jch.12013
- Issue published online: 5 NOV 2012
- Article first published online: 3 OCT 2012
- Manuscript received: February 7, 2012; revised: August 1, 2012; accepted: August 2, 2012
J Clin Hypertens (Greenwich). 2012;14:760–766. ©2012 Wiley Periodicals, Inc.
This study analyzed the cost-effectiveness of a patient hypertension education intervention that provided patient education through interactive voice response technology and distribution of automated blood pressure monitors to high-risk plan members with uncontrolled hypertension. A total of 17,318 members were identified with hypertension in an administrative database. The study sample consisted of all 534 high-risk hypertensive plan members who received blood pressure monitors. Using data on activity-based program costs and changes in hypertension control, this study modeled the intervention’s cost-effectiveness relative to no intervention. The intervention was estimated to have brought hypertension under control in 151 patients during the study year. Across all 534 participants in 1 year, 0.3 events (acute myocardial infarction, stroke, congestive heart failure, and renal failure) were avoided and 2.77 life-years were gained (LYG). The incremental cost-effectiveness ratio (ICER) for the intervention compared with no intervention was $767 per person brought under control or $41,927 per LYG. If the gains in hypertension control from 1 year’s investment were assumed to last 10 years, the 10-year ICER relative to no intervention was $1857 per LYG. The intervention is a cost-effective strategy to address hypertension and can serve as a model for future innovations.